Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous platelet-rich plasma plus routine treatment for premature ovarian failure during ICSI
IRCT20250313065056N1Phase 3Completed
- Sponsor
- Kurdistan University of Medical Sciences
- Start
- Oct 2025
- Modality
- Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of autologous platelet-rich plasma in ovarian hypofunction (POI) and infertility (2 arms), sponsored by Kurdistan University of Medical Sciences. Primary endpoints: Improvement in oocyte quality, Number of mature oocytes and 1 more. Started Oct 2025; status: completed.
02
Drugs
autologous platelet-rich plasma
03
Conditions
ovarian hypofunction (POI)infertility
Beyond the preview
Go deeper on IRCT20250313065056N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250313065056N1.